Table 3.
Concordance in molecular classification between cervicovaginal and tumor samples.
| Tumour samples | Clinician-collected samples |
Self-collected samples |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| POLE mutated | Hyper-mutated | TP53 mutated | NSMP | Total | % Correct | Kappa |
POLE mutated | Hyper-mutated | TP53 mutated | NSMP | Total | % Correct | Kappa |
|
| (95% CI) | (95% CI) | |||||||||||||
| POLE Sanger availablea | POLE Sanger availableb | |||||||||||||
| POLE mutated | 5 | 0 | 0 | 1 | 6 | 83% | 0.703 | 4 | 0 | 1 | 0 | 5 | 80% | 0.739 |
| MMR-deficient | 0 | 10 | 0 | 0 | 10 | 100% | (0.543–0.863) | 0 | 9 | 0 | 0 | 9 | 100% | (0.552–0.927) |
| p53 abnormal | 0 | 1 | 16 | 5 | 22 | 73% | 0 | 0 | 13 | 4 | 17 | 76% | ||
| NSMP | 1 | 2 | 0 | 6 | 9 | 67% | 0 | 0 | 1 | 2 | 3 | 67% | ||
| Total | 6 | 13 | 16 | 12 | 47 | 79% | 4 | 9 | 15 | 6 | 34 | 82% | ||
| All | All | |||||||||||||
| MMR-deficient | NA | 11 | 1 | 1 | 13 | 85% | 0.585 | NA | 10 | 1 | 2 | 13 | 77% | 0.625 |
| p53 abnormal | NA | 1 | 17 | 6 | 24 | 71% | (0.436–0.734) | NA | 0 | 14 | 5 | 19 | 74% | (0.456–0.794) |
| NSMP | NA | 8 | 5 | 39 | 52 | 75% | NA | 2 | 5 | 26 | 33 | 79% | ||
| Total | NA | 20 | 23 | 46 | 89 | 75% | NA | 12 | 20 | 33 | 65 | 77% | ||
| All, excluding POLEmut casesc | All, excluding POLEmut casesd | |||||||||||||
| MMR-deficient | NA | 11 | 0 | 1 | 12 | 92% | 0.636 | NA | 10 | 0 | 2 | 12 | 83% | 0.714 |
| p53 abnormal | NA | 1 | 16 | 6 | 23 | 70% | (0.484–0.787) | NA | 0 | 13 | 5 | 18 | 72% | (0.553–0.876) |
| NSMP | NA | 8 | 1 | 32 | 41 | 78% | NA | 2 | 1 | 23 | 26 | 88% | ||
| Total | NA | 20 | 17 | 39 | 76 | 78% | NA | 12 | 14 | 30 | 56 | 82% | ||
NA = Not available; CI = Confidence interval; NSMP = No specific molecular profile.
Bold indicates the number of concordant classifications.
a
40 High-grade cancers and 7 low-grade cancers.
b
31 High-grade cancers and 3 low-grade cancers.
c
Excluding 5 POLE mutated cases jointly identified in tumor and cervicovaginal samples, 1 POLE mutated identified in tumor samples, and 7 POLE mutated cases identified in cervicovaginal samples.
d
Excluding 4 POLE mutated cases jointly identified in tumor and cervicovaginal samples, 1 POLE mutated identified in tumor samples, and 4 POLE mutated cases identified in cervicovaginal samples.